Gilead Sciences (GILD) Financials

$106.50 +2.87 (+2.77%)

Closing price 04/14/2025 04:00 PM Eastern

Extended Trading

$106.26 -0.24 (-0.23%)

As of 07:00 AM Eastern

Annual Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	18,108	13,501	4,628	5,455	5,386	123	6,225	4,592	5,665	480
Consolidated Net Income / (Loss)	18,106	13,488	4,644	5,460	5,364	89	6,201	4,566	5,613	480
Net Income / (Loss) Continuing Operations	18,106	13,488	4,644	5,460	5,364	89	6,201	4,566	5,612	479
Total Pre-Tax Income	21,659	17,097	13,529	7,799	5,160	1,669	8,278	5,814	6,859	690
Total Operating Income	22,193	17,633	14,124	8,200	4,287	4,071	9,918	7,330	7,605	1,662
Total Gross Profit	28,633	26,129	21,736	17,274	17,774	20,117	20,704	21,624	20,618	22,503
Total Revenue	32,639	30,390	26,107	22,127	22,449	24,689	27,305	27,281	27,116	28,754
Operating Revenue	32,151	30,390	26,107	22,127	22,449	24,689	27,305	27,281	27,116	28,754
Total Cost of Revenue	4,006	4,261	4,371	4,853	4,675	4,572	6,601	5,657	6,498	6,251
Operating Cost of Revenue	4,006	4,261	4,371	4,853	4,675	4,572	6,601	5,657	6,498	6,251
Total Operating Expenses	6,440	8,496	7,612	9,074	13,487	16,046	10,786	14,294	13,013	20,841
Selling, General & Admin Expense	3,426	3,398	3,878	4,056	4,381	5,151	5,246	5,673	6,090	6,091
Research & Development Expense	3,014	5,098	3,734	5,018	9,106	10,895	5,540	5,921	6,873	10,570
Impairment Charge	-	-	-	-	-	0.00	0.00	2,700	50	4,180
Total Other Income / (Expense), net	-534	-536	-595	-401	873	-2,402	-1,640	-1,516	-746	-971
Interest Expense	688	964	1,118	1,077	995	984	1,001	935	944	977
Other Income / (Expense), net	154	428	523	676	1,868	-1,418	-639	-581	198	6.00
Income Tax Expense	3,553	3,609	8,885	2,339	-204	1,580	2,077	1,248	1,247	211
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.00	-13	16	5.00	-22	-34	-24	-26	-52	0.00
Basic Earnings per Share	$12.37	$10.08	$3.54	$4.20	$4.24	$0.10	$4.96	$3.66	$4.54	$0.38
Weighted Average Basic Shares Outstanding	1.46B	1.34B	1.31B	1.30B	1.27B	1.26B	1.26B	1.26B	1.25B	1.25B
Diluted Earnings per Share	$11.91	$9.94	$3.51	$4.17	$4.22	$0.10	$4.93	$3.64	$4.50	$0.38
Weighted Average Diluted Shares Outstanding	1.52B	1.36B	1.32B	1.31B	1.28B	1.26B	1.26B	1.26B	1.26B	1.26B
Weighted Average Basic & Diluted Shares Outstanding	1.46B	1.34B	1.31B	1.30B	1.26B	1.26B	1.25B	1.25B	1.25B	1.25B
Cash Dividends to Common per Share	$1.29	$1.84	$2.08	$2.28	$2.52	$2.72	$2.84	$2.92	$3.00	$3.08

This table shows Gilead Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	1,789	1,640	1,010	1,045	2,180	1,430	-4,170	1,614	1,253	1,783
Consolidated Net Income / (Loss)	1,786	1,633	985	1,039	2,172	1,417	-4,170	1,614	1,253	1,783
Net Income / (Loss) Continuing Operations	1,786	1,633	984	1,039	2,172	1,417	-4,171	1,615	1,253	1,782
Total Pre-Tax Income	2,432	2,031	1,300	1,588	2,318	1,653	-4,486	2,053	956	2,167
Total Operating Income	2,837	2,267	1,705	1,665	2,623	1,612	-4,322	2,644	888	2,452
Total Gross Profit	5,647	5,993	4,951	5,157	5,486	5,024	5,134	5,410	5,971	5,988
Total Revenue	7,042	7,389	6,352	6,599	7,051	7,114	6,686	6,954	7,545	7,569
Operating Revenue	7,042	7,389	6,352	6,599	7,051	7,114	6,686	6,954	7,545	7,569
Total Cost of Revenue	1,395	1,396	1,401	1,442	1,565	2,090	1,552	1,544	1,574	1,581
Operating Cost of Revenue	1,395	1,396	1,401	1,442	1,565	2,090	1,552	1,544	1,574	1,581
Total Operating Expenses	2,810	3,726	3,247	3,492	2,863	3,411	9,456	2,766	5,083	3,536
Selling, General & Admin Expense	1,213	2,020	1,319	1,849	1,315	1,607	1,375	1,377	1,433	1,906
Research & Development Expense	1,597	1,706	1,928	1,643	1,548	1,754	5,651	1,389	1,900	1,630
Total Other Income / (Expense), net	-405	-236	-404	-78	-304	40	-163	-592	68	-284
Interest Expense	229	226	230	230	232	252	254	237	238	248
Other Income / (Expense), net	-176	-10	-174	152	-72	292	91	-355	306	-36
Income Tax Expense	646	398	316	549	146	236	-315	438	-297	385
Basic Earnings per Share	$1.43	$1.30	$0.81	$0.84	$1.75	$1.14	($3.34)	$1.29	$1.00	$1.43
Weighted Average Basic Shares Outstanding	1.26B	1.26B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B
Diluted Earnings per Share	$1.42	$1.29	$0.80	$0.83	$1.73	$1.14	($3.34)	$1.29	$1.00	$1.43
Weighted Average Diluted Shares Outstanding	1.26B	1.26B	1.26B	1.26B	1.26B	1.26B	1.25B	1.25B	1.25B	1.26B
Weighted Average Basic & Diluted Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.24B	1.25B	1.25B

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	2,824	-4,622	-778	10,437	-6,309	-5,634	-659	74	673	3,906
Net Cash From Operating Activities	21,250	17,047	11,898	8,400	9,144	8,168	11,384	9,072	8,006	10,828
Net Cash From Continuing Operating Activities	21,250	17,047	11,898	8,400	9,144	8,168	11,384	9,072	8,005	10,828
Net Income / (Loss) Continuing Operations	18,106	13,488	4,644	5,460	5,364	89	6,201	4,566	5,613	480
Consolidated Net Income / (Loss)	18,106	13,488	4,644	5,460	5,364	89	6,201	4,566	5,613	480
Depreciation Expense	161	177	233	226	255	288	329	323	354	381
Amortization Expense	937	981	1,053	1,203	1,149	1,192	1,721	1,780	2,339	2,386
Non-Cash Adjustments To Reconcile Net Income	944	974	942	2,161	5,272	8,451	2,760	5,718	2,964	10,305
Changes in Operating Assets and Liabilities, net	1,102	1,427	5,026	-650	-2,896	-1,852	373	-3,315	-3,265	-2,724
Net Cash From Investing Activities	-12,475	-11,985	-16,069	14,355	-7,817	-14,615	-3,131	-2,466	-2,265	-3,449
Net Cash From Continuing Investing Activities	-12,475	-11,985	-16,069	14,355	-7,817	-14,615	-3,131	-2,466	-2,266	-3,449
Purchase of Property, Plant & Equipment	-747	-748	-590	-924	-825	-650	-579	-728	-585	-523
Acquisitions	0.00	0.00	-10,426	0.00	-4,251	-25,920	-1,584	-1,797	-1,152	-4,840
Purchase of Investments	-17,239	-25,976	-23,314	-10,389	-32,228	-20,770	-3,897	-1,942	-2,372	-736
Sale and/or Maturity of Investments	5,511	14,739	18,261	25,858	29,921	32,718	2,910	2,002	1,844	2,592
Other Investing Activities, net	-	-	0.00	-190	-434	7.00	19	-1.00	-1.00	58
Net Cash From Financing Activities	-5,884	-9,725	3,393	-12,318	-7,634	770	-8,877	-6,469	-5,125	-3,433
Net Cash From Continuing Financing Activities	-5,884	-9,725	3,393	-12,318	-7,634	770	-8,877	-6,469	-5,126	-3,433
Repayment of Debt	-5,013	-2,257	-2,141	-6,736	-2,872	-2,638	-4,895	-1,673	-2,529	-2,251
Repurchase of Common Equity	-10,002	-11,001	-954	-2,900	-1,749	-1,583	-546	-1,396	-1,000	-1,150
Payment of Dividends	-1,874	-2,455	-2,731	-2,971	-3,222	-3,449	-3,605	-3,709	-3,809	-3,918
Issuance of Debt	9,902	5,293	8,985	0.00	-	8,184	0.00	0.00	1,980	3,464
Issuance of Common Equity	319	208	234	289	209	256	169	309	232	422
Effect of Exchange Rate Changes	-67	41	-	-	-2.00	43	-35	-63	57	-40
Cash Interest Paid	529	885	1,038	1,070	982	951	979	907	891	951
Cash Income Taxes Paid	3,137	2,436	3,342	3,198	1,793	2,639	2,509	3,136	3,990	2,779

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-40	713	-476	768	1.00	380	-1,367	-1,946	2,264	4,955
Net Cash From Operating Activities	2,863	2,567	1,744	2,338	1,755	2,169	2,219	1,325	4,309	2,975
Net Cash From Continuing Operating Activities	2,863	2,567	1,745	2,337	1,756	2,167	2,219	1,324	4,309	2,976
Net Income / (Loss) Continuing Operations	1,786	1,633	985	1,039	2,172	1,417	-4,170	1,614	1,253	1,783
Consolidated Net Income / (Loss)	1,786	1,633	985	1,039	2,172	1,417	-4,170	1,614	1,253	1,783
Depreciation Expense	80	83	94	83	86	91	94	98	94	95
Amortization Expense	445	445	546	598	598	597	596	596	596	598
Non-Cash Adjustments To Reconcile Net Income	939	627	965	507	517	975	6,881	728	2,300	396
Changes in Operating Assets and Liabilities, net	-387	-221	-845	110	-1,617	-913	-1,182	-1,712	66	104
Net Cash From Investing Activities	-713	-375	-826	-483	-229	-727	-2,207	-307	-710	-225
Net Cash From Continuing Investing Activities	-713	-375	-826	-483	-229	-728	-2,205	-309	-709	-226
Purchase of Property, Plant & Equipment	-157	-181	-109	-139	-122	-215	-105	-130	-141	-147
Acquisitions	-448	-218	-551	-243	-79	-279	-4,043	-152	-570	-75
Purchase of Investments	-430	-378	-652	-645	-395	-680	-654	-34	-9.00	-39
Other Investing Activities, net	-2.00	2.00	-5.00	-1.00	6.00	-1.00	5.00	7.00	11	35
Net Cash From Financing Activities	-2,118	-1,554	-1,406	-1,101	-1,519	-1,099	-1,361	-2,953	-1,379	2,260
Net Cash From Continuing Financing Activities	-2,118	-1,554	-1,407	-1,100	-1,519	-1,100	-1,360	-2,954	-1,379	2,260
Repayment of Debt	-1,045	-23	-135	-32	-2,328	-34	-116	-1,887	-194	-54
Repurchase of Common Equity	-180	-792	-400	-150	-300	-150	-400	-100	-300	-350
Payment of Dividends	-929	-915	-969	-944	-953	-943	-990	-972	-983	-973
Issuance of Debt	-	-	-	-	-	1.00	-	-	-	3,464
Issuance of Common Equity	36	176	97	26	83	26	146	5.00	98	173
Effect of Exchange Rate Changes	-72	75	13	13	-6.00	37	-18	-11	44	-55

This table presents Gilead Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	51,716	56,977	70,283	63,675	61,627	68,407	67,952	63,171	62,125	58,995
Total Current Assets	24,762	19,588	31,823	35,836	30,296	15,996	14,772	14,443	16,085	19,173
Cash & Equivalents	12,851	8,229	7,588	17,940	11,631	5,997	5,338	5,412	6,085	9,991
Short-Term Investments	1,756	3,666	17,922	12,149	12,721	1,411	1,182	973	1,179	0.00
Accounts Receivable	5,854	4,514	3,851	3,327	3,582	4,892	4,493	4,777	4,660	4,420
Inventories, net	1,955	1,587	801	814	922	1,683	1,618	1,507	1,787	1,710
Prepaid Expenses	1,518	1,592	1,661	1,606	1,440	2,013	2,141	1,774	2,374	3,052
Plant, Property, & Equipment, net	2,276	2,865	3,295	4,006	4,502	4,967	5,121	5,475	5,317	5,414
Total Noncurrent Assets	24,678	34,524	35,165	23,833	26,829	47,444	48,059	43,253	40,723	34,408
Long-Term Investments	11,601	20,485	11,184	1,423	1,488	502	1,309	1,245	1,163	0.00
Goodwill	1,172	1,172	4,159	4,117	4,117	8,108	8,332	8,314	8,314	8,314
Intangible Assets	10,247	8,971	17,100	15,738	13,786	33,126	33,455	28,894	26,454	19,948
Other Noncurrent Operating Assets	1,334	3,896	2,722	2,555	7,438	5,708	4,963	4,800	4,792	6,146
Total Liabilities & Shareholders' Equity	51,716	56,977	70,283	63,675	61,627	68,407	67,952	63,171	62,125	58,995
Total Liabilities	32,601	37,614	49,782	42,141	38,977	50,186	46,888	41,962	39,376	39,749
Total Current Liabilities	9,890	9,218	11,635	10,605	9,759	11,397	11,610	11,237	11,280	12,004
Short-Term Debt	982	0.00	2,747	2,748	2,499	2,757	1,516	2,273	1,798	1,815
Accounts Payable	1,178	1,206	814	790	713	5,180	705	905	550	833
Accrued Expenses	7,290	8,012	8,074	7,067	6,547	3,460	3,244	3,479	3,802	3,892
Other Current Liabilities	-	-	-	-	-	-	6,145	4,580	5,130	5,464
Total Noncurrent Liabilities	22,711	28,396	38,147	31,536	29,218	38,789	35,278	30,725	28,096	27,745
Long-Term Debt	21,073	26,346	30,795	24,574	22,094	28,645	25,179	22,957	23,189	24,896
Noncurrent Deferred Revenue	1,243	1,753	6,794	5,922	6,115	5,016	4,767	3,916	2,039	830
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	3,914	4,356	2,673	1,588	724
Other Noncurrent Operating Liabilities	395	297	558	1,040	1,009	1,214	976	1,179	1,280	1,295
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	19,113	19,363	20,501	21,534	22,650	18,221	21,064	21,209	22,749	19,246
Total Preferred & Common Equity	18,534	18,887	20,442	21,387	22,525	18,202	21,069	21,240	22,833	19,330
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	18,534	18,887	20,442	21,387	22,525	18,202	21,069	21,240	22,833	19,330
Common Stock	445	455	1,265	2,283	3,052	3,881	4,662	5,551	6,501	7,701
Retained Earnings	18,001	18,154	19,012	19,024	19,388	14,381	16,324	15,687	16,304	11,497
Accumulated Other Comprehensive Income / (Loss)	88	278	165	80	85	-60	83	2.00	28	132
Noncontrolling Interest	579	476	59	147	125	19	-5.00	-31	-84	-84

This table presents Gilead Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Total Assets	62,557	63,171	61,876	62,337	62,373	62,125	56,292	53,579	54,525	58,995
Total Current Assets	13,554	14,443	13,456	14,287	15,980	16,085	14,041	12,317	14,779	19,173
Cash & Equivalents	4,699	5,412	4,936	5,704	5,705	6,085	4,718	2,772	5,037	9,991
Short-Term Investments	961	973	936	963	1,159	1,179	0.00	0.00	0.00	0.00
Accounts Receivable	4,354	4,777	4,162	4,229	4,790	4,660	4,669	4,663	4,587	4,420
Inventories, net	1,463	1,507	1,576	1,633	1,663	1,787	1,853	2,026	1,869	1,710
Prepaid Expenses	2,077	1,774	1,846	1,757	2,662	2,374	2,800	2,856	3,287	3,052
Plant, Property, & Equipment, net	5,349	5,475	5,479	5,540	5,572	5,317	5,321	5,346	5,391	5,414
Total Noncurrent Assets	43,654	43,253	42,941	42,511	40,822	40,723	36,930	35,916	34,354	34,408
Long-Term Investments	1,282	1,245	1,327	1,334	1,156	1,163	0.00	0.00	0.00	0.00
Goodwill	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314
Intangible Assets	29,440	28,894	28,348	27,750	27,152	26,454	23,428	22,832	20,546	19,948
Other Noncurrent Operating Assets	4,618	4,800	4,952	5,113	4,200	4,792	5,188	4,770	5,494	6,146
Total Liabilities & Shareholders' Equity	62,557	63,171	61,876	62,337	62,373	62,125	56,292	53,579	54,525	58,995
Total Liabilities	41,500	41,962	40,937	41,243	40,130	39,376	38,837	35,384	36,134	39,749
Total Current Liabilities	10,423	11,237	10,528	13,964	11,945	11,280	13,015	10,781	11,725	12,004
Short-Term Debt	2,270	2,273	2,283	4,037	1,793	1,798	3,667	1,810	1,812	1,815
Accounts Payable	614	905	627	622	586	550	622	537	903	833
Accrued Expenses	7,539	3,479	3,477	3,494	3,714	3,802	4,263	3,923	4,113	3,892
Other Current Liabilities	-	4,580	4,140	5,810	5,852	5,130	4,464	4,510	4,896	5,464
Total Noncurrent Liabilities	31,077	30,725	30,409	27,279	28,185	28,096	25,822	24,603	24,409	27,745
Long-Term Debt	22,953	22,957	22,956	21,209	23,189	23,189	21,527	21,540	21,437	24,896
Noncurrent Deferred Revenue	3,982	3,916	3,775	2,610	2,088	2,039	1,967	738	782	830
Noncurrent Deferred & Payable Income Tax Liabilities	3,036	2,673	2,401	2,106	1,984	1,588	933	907	794	724
Other Noncurrent Operating Liabilities	1,106	1,179	1,277	1,354	924	1,280	1,395	1,418	1,396	1,295
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	21,057	21,209	20,939	21,094	22,242	22,749	17,455	18,197	18,390	19,246
Total Preferred & Common Equity	21,081	21,240	20,997	21,158	22,314	22,833	17,539	18,281	18,475	19,330
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	21,081	21,240	20,997	21,157	22,313	22,833	17,539	18,281	18,474	19,330
Common Stock	5,227	5,551	5,794	6,009	6,280	6,501	6,814	7,023	7,328	7,701
Retained Earnings	15,756	15,687	15,223	15,138	16,002	16,304	10,656	11,165	11,073	11,497
Accumulated Other Comprehensive Income / (Loss)	98	2.00	-20	10	31	28	69	93	73	132
Noncontrolling Interest	-24	-31	-58	-64	-72	-84	-84	-84	-84	-84

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	31.13%	-6.89%	-14.09%	-15.25%	1.46%	9.98%	10.60%	-0.09%	-0.60%	6.04%
EBITDA Growth	43.68%	-18.03%	-17.10%	-35.32%	-26.65%	-45.32%	174.11%	-21.86%	18.57%	-57.75%
EBIT Growth	46.36%	-19.18%	-18.90%	-39.40%	-30.66%	-56.90%	249.76%	-27.27%	15.62%	-78.62%
NOPAT Growth	49.72%	-25.02%	-65.15%	18.41%	-22.37%	-95.13%	3,322.36%	-22.52%	8.09%	-81.46%
Net Income Growth	50.15%	-25.51%	-65.57%	17.57%	-1.76%	-98.34%	6,867.42%	-26.37%	22.93%	-91.45%
EPS Growth	62.04%	-16.54%	-64.69%	18.80%	1.20%	-97.63%	4,830.00%	-26.17%	23.63%	-91.56%
Operating Cash Flow Growth	65.78%	-19.78%	-30.20%	-29.40%	8.86%	-10.67%	39.37%	-20.31%	-11.75%	35.25%
Free Cash Flow Firm Growth	71.04%	-22.68%	-94.67%	593.73%	-93.08%	-5,155.00%	145.85%	-25.35%	-16.80%	-21.42%
Invested Capital Growth	-9.39%	-10.91%	30.16%	-0.03%	23.40%	94.89%	-4.27%	-2.81%	1.29%	-8.50%
Revenue Q/Q Growth	3.79%	-3.76%	-4.99%	-0.69%	0.38%	6.66%	-0.64%	0.53%	-1.00%	1.61%
EBITDA Q/Q Growth	5.92%	-7.10%	-9.42%	-10.34%	12.89%	0.34%	-7.93%	16.49%	-1.81%	13.20%
EBIT Q/Q Growth	6.21%	-7.58%	-10.74%	-11.47%	16.48%	-2.32%	-10.46%	22.96%	-4.33%	44.29%
NOPAT Q/Q Growth	7.52%	-10.57%	-59.59%	237.55%	63.99%	-87.71%	-19.08%	31.63%	-6.46%	116.70%
Net Income Q/Q Growth	7.24%	-10.52%	-59.89%	236.83%	100.30%	-92.79%	-15.85%	37.99%	-3.71%	321.05%
EPS Q/Q Growth	3.03%	-7.71%	-60.02%	239.02%	100.95%	-89.80%	-16.16%	37.36%	-3.23%	322.22%
Operating Cash Flow Q/Q Growth	15.01%	-11.69%	-6.20%	-4.63%	2.64%	-7.52%	12.77%	-6.57%	-4.74%	8.04%
Free Cash Flow Firm Q/Q Growth	12.90%	-12.65%	-92.90%	224.28%	-79.35%	-1,614.20%	174.14%	-6.50%	-15.66%	43.51%
Invested Capital Q/Q Growth	-0.64%	3.97%	31.87%	-10.97%	5.57%	101.40%	-5.65%	-1.34%	0.27%	-1.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.73%	85.98%	83.26%	78.07%	79.18%	81.48%	75.82%	79.26%	76.04%	78.26%
EBITDA Margin	71.83%	63.24%	61.03%	46.57%	33.67%	16.74%	41.49%	32.45%	38.71%	15.42%
Operating Margin	68.00%	58.02%	54.10%	37.06%	19.10%	16.49%	36.32%	26.87%	28.05%	5.78%
EBIT Margin	68.47%	59.43%	56.10%	40.11%	27.42%	10.75%	33.98%	24.74%	28.78%	5.80%
Profit (Net Income) Margin	55.47%	44.38%	17.79%	24.68%	23.89%	0.36%	22.71%	16.74%	20.70%	1.67%
Tax Burden Percent	83.60%	78.89%	34.33%	70.01%	103.95%	5.33%	74.91%	78.53%	81.83%	69.57%
Interest Burden Percent	96.92%	94.66%	92.37%	87.87%	83.83%	62.91%	89.21%	86.15%	87.90%	41.37%
Effective Tax Rate	16.40%	21.11%	65.67%	29.99%	-3.95%	94.67%	25.09%	21.47%	18.18%	30.58%
Return on Invested Capital (ROIC)	117.89%	98.34%	31.61%	33.09%	23.00%	0.69%	18.20%	14.62%	15.93%	3.07%
ROIC Less NNEP Spread (ROIC-NNEP)	143.58%	106.64%	36.05%	40.74%	-10.38%	-0.46%	12.40%	8.09%	12.36%	-0.98%
Return on Net Nonoperating Assets (RNNOA)	-14.28%	-28.23%	-8.31%	-7.12%	1.28%	-0.25%	13.37%	6.98%	9.61%	-0.78%
Return on Equity (ROE)	103.61%	70.11%	23.30%	25.98%	24.28%	0.44%	31.57%	21.60%	25.54%	2.29%
Cash Return on Invested Capital (CROIC)	127.74%	109.89%	5.40%	33.12%	2.05%	-63.67%	22.57%	17.47%	14.65%	11.95%
Operating Return on Assets (OROA)	51.74%	33.23%	23.02%	13.25%	9.82%	4.08%	13.61%	10.29%	12.46%	2.75%
Return on Assets (ROA)	41.92%	24.82%	7.30%	8.15%	8.56%	0.14%	9.10%	6.96%	8.96%	0.79%
Return on Common Equity (ROCE)	100.68%	68.18%	22.99%	25.85%	24.13%	0.43%	31.56%	21.62%	25.60%	2.30%
Return on Equity Simple (ROE_SIMPLE)	97.69%	71.41%	22.72%	25.53%	23.81%	0.49%	29.43%	21.50%	24.58%	2.48%
Net Operating Profit after Tax (NOPAT)	18,552	13,911	4,848	5,741	4,456	217	7,430	5,757	6,222	1,154
NOPAT Margin	56.84%	45.77%	18.57%	25.94%	19.85%	0.88%	27.21%	21.10%	22.95%	4.01%
Net Nonoperating Expense Percent (NNEP)	-25.69%	-8.30%	-4.45%	-7.65%	33.38%	1.15%	5.80%	6.53%	3.57%	4.05%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	12.40%	13.04%	2.51%
Cost of Revenue to Revenue	12.27%	14.02%	16.74%	21.93%	20.83%	18.52%	24.18%	20.74%	23.96%	21.74%
SG&A Expenses to Revenue	10.50%	11.18%	14.85%	18.33%	19.52%	20.86%	19.21%	20.79%	22.46%	21.18%
R&D to Revenue	9.23%	16.78%	14.30%	22.68%	40.56%	44.13%	20.29%	21.70%	25.35%	36.76%
Operating Expenses to Revenue	19.73%	27.96%	29.16%	41.01%	60.08%	64.99%	39.50%	52.40%	47.99%	72.48%
Earnings before Interest and Taxes (EBIT)	22,347	18,061	14,647	8,876	6,155	2,653	9,279	6,749	7,803	1,668
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	23,445	19,219	15,933	10,305	7,559	4,133	11,329	8,852	10,496	4,435
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.79	3.76	3.55	3.02	3.03	3.46	3.89	4.69	4.25	5.96
Price to Tangible Book Value (P/TBV)	15.08	8.12	0.00	42.21	14.76	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.29	2.34	2.78	2.92	3.04	2.55	3.00	3.65	3.58	4.00
Price to Earnings (P/E)	5.92	5.26	15.66	11.85	12.67	512.71	13.17	21.69	17.12	239.83
Dividend Yield	1.73%	3.41%	3.75%	4.56%	4.67%	5.41%	4.34%	3.68%	3.85%	3.33%
Earnings Yield	16.88%	19.01%	6.39%	8.44%	7.90%	0.20%	7.59%	4.61%	5.84%	0.42%
Enterprise Value to Invested Capital (EV/IC)	6.93	4.91	4.00	3.49	3.13	2.08	2.53	3.02	2.89	3.66
Enterprise Value to Revenue (EV/Rev)	3.18	2.15	2.66	2.74	2.99	3.51	3.69	4.30	4.18	4.58
Enterprise Value to EBITDA (EV/EBITDA)	4.42	3.41	4.36	5.88	8.88	20.95	8.90	13.24	10.81	29.71
Enterprise Value to EBIT (EV/EBIT)	4.64	3.62	4.74	6.83	10.90	32.63	10.87	17.36	14.54	78.99
Enterprise Value to NOPAT (EV/NOPAT)	5.59	4.70	14.31	10.56	15.06	398.80	13.58	20.35	18.23	114.19
Enterprise Value to Operating Cash Flow (EV/OCF)	4.88	3.84	5.83	7.22	7.34	10.60	8.86	12.92	14.17	12.17
Enterprise Value to Free Cash Flow (EV/FCFF)	5.16	4.21	83.78	10.55	168.80	0.00	10.95	17.04	19.83	29.30
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.15	1.36	1.64	1.27	1.09	1.72	1.27	1.19	1.10	1.39
Long-Term Debt to Equity	1.10	1.36	1.50	1.14	0.98	1.57	1.20	1.08	1.02	1.29
Financial Leverage	-0.10	-0.26	-0.23	-0.17	-0.12	0.54	1.08	0.86	0.78	0.79
Leverage Ratio	2.47	2.82	3.19	3.19	2.84	3.18	3.47	3.10	2.85	2.88
Compound Leverage Factor	2.40	2.67	2.95	2.80	2.38	2.00	3.10	2.67	2.51	1.19
Debt to Total Capital	53.57%	57.64%	62.07%	55.92%	52.06%	63.28%	55.90%	54.33%	52.34%	58.12%
Short-Term Debt to Total Capital	2.39%	0.00%	5.08%	5.62%	5.29%	5.56%	3.17%	4.89%	3.77%	3.95%
Long-Term Debt to Total Capital	51.19%	57.64%	56.98%	50.30%	46.77%	57.73%	52.72%	49.43%	48.58%	54.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.41%	1.04%	0.11%	0.30%	0.26%	0.04%	-0.01%	-0.07%	-0.18%	-0.18%
Common Equity to Total Capital	45.02%	41.32%	37.83%	43.78%	47.68%	36.68%	44.12%	45.74%	47.83%	42.06%
Debt to EBITDA	0.94	1.37	2.11	2.65	3.25	7.60	2.36	2.85	2.38	6.02
Net Debt to EBITDA	-0.18	-0.31	-0.20	-0.41	-0.17	5.68	1.67	1.99	1.58	3.77
Long-Term Debt to EBITDA	0.90	1.37	1.93	2.38	2.92	6.93	2.22	2.59	2.21	5.61
Debt to NOPAT	1.19	1.89	6.92	4.76	5.52	144.65	3.59	4.38	4.02	23.15
Net Debt to NOPAT	-0.22	-0.43	-0.65	-0.73	-0.28	108.21	2.54	3.06	2.66	14.49
Long-Term Debt to NOPAT	1.14	1.89	6.35	4.28	4.96	131.95	3.39	3.99	3.73	21.58
Altman Z-Score	4.86	3.38	2.66	2.62	2.58	1.62	2.29	2.62	2.79	2.74
Noncontrolling Interest Sharing Ratio	2.83%	2.75%	1.34%	0.49%	0.62%	0.35%	0.04%	-0.09%	-0.26%	-0.40%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.50	2.13	2.74	3.38	3.10	1.40	1.27	1.29	1.43	1.60
Quick Ratio	2.07	1.78	2.52	3.15	2.86	1.08	0.95	0.99	1.06	1.20
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	20,102	15,544	828	5,746	397	-20,093	9,213	6,878	5,722	4,497
Operating Cash Flow to CapEx	2,844.71%	2,279.01%	2,016.61%	909.09%	1,108.36%	1,256.62%	1,966.15%	1,246.15%	1,368.55%	2,070.36%
Free Cash Flow to Firm to Interest Expense	29.22	16.12	0.74	5.33	0.40	-20.42	9.20	7.36	6.06	4.60
Operating Cash Flow to Interest Expense	30.89	17.68	10.64	7.80	9.19	8.30	11.37	9.70	8.48	11.08
Operating Cash Flow Less CapEx to Interest Expense	29.80	16.91	10.11	6.94	8.36	7.64	10.79	8.92	7.86	10.55
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.76	0.56	0.41	0.33	0.36	0.38	0.40	0.42	0.43	0.47
Accounts Receivable Turnover	6.22	5.86	6.24	6.17	6.50	5.83	5.82	5.89	5.75	6.33
Inventory Turnover	2.40	2.41	3.66	6.01	5.39	3.51	4.00	3.62	3.95	3.58
Fixed Asset Turnover	16.53	11.82	8.48	6.06	5.28	5.21	5.41	5.15	5.03	5.36
Accounts Payable Turnover	3.76	3.57	4.33	6.05	6.22	1.55	2.24	7.03	8.93	9.04
Days Sales Outstanding (DSO)	58.65	62.26	58.48	59.20	56.17	62.64	62.73	62.01	63.51	57.63
Days Inventory Outstanding (DIO)	152.20	151.71	99.70	60.73	67.77	103.98	91.26	100.82	92.51	102.10
Days Payable Outstanding (DPO)	97.17	102.11	84.34	60.32	58.67	235.23	162.70	51.94	40.86	40.38
Cash Conversion Cycle (CCC)	113.68	111.86	73.84	59.62	65.26	-68.61	-8.71	110.89	115.16	119.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	14,962	13,329	17,349	17,344	21,403	41,713	39,930	38,809	39,309	35,966
Invested Capital Turnover	2.07	2.15	1.70	1.28	1.16	0.78	0.67	0.69	0.69	0.76
Increase / (Decrease) in Invested Capital	-1,550	-1,633	4,020	-5.00	4,059	20,310	-1,783	-1,121	500	-3,343
Enterprise Value (EV)	103,699	65,444	69,388	60,616	67,097	86,575	100,871	117,171	113,455	131,754
Market Capitalization	107,271	71,002	72,481	64,659	68,219	63,064	82,010	99,602	96,979	115,118
Book Value per Share	$12.86	$14.34	$15.65	$16.53	$17.80	$14.52	$16.80	$16.93	$18.32	$15.51
Tangible Book Value per Share	$4.94	$6.64	($0.63)	$1.18	$3.65	($18.37)	($16.52)	($12.73)	($9.58)	($7.17)
Total Capital	41,170	45,709	54,043	48,856	47,243	49,623	47,759	46,439	47,736	45,957
Total Debt	22,055	26,346	33,542	27,322	24,593	31,402	26,695	25,230	24,987	26,711
Total Long-Term Debt	21,073	26,346	30,795	24,574	22,094	28,645	25,179	22,957	23,189	24,896
Net Debt	-4,153	-6,034	-3,152	-4,190	-1,247	23,492	18,866	17,600	16,560	16,720
Capital Expenditures (CapEx)	747	748	590	924	825	650	579	728	585	523
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,247	-1,525	-2,575	-2,110	-1,316	-52	-1,842	-906	-661	-1,007
Debt-free Net Working Capital (DFNWC)	15,854	10,370	22,935	27,979	23,036	7,356	4,678	5,479	6,603	8,984
Net Working Capital (NWC)	14,872	10,370	20,188	25,231	20,537	4,599	3,162	3,206	4,805	7,169
Net Nonoperating Expense (NNE)	446	423	204	281	-908	128	1,229	1,191	609	674
Net Nonoperating Obligations (NNO)	-4,153	-6,034	-3,152	-4,190	-1,247	23,492	18,866	17,600	16,560	16,720
Total Depreciation and Amortization (D&A)	1,098	1,158	1,286	1,429	1,404	1,480	2,050	2,103	2,693	2,767
Debt-free, Cash-free Net Working Capital to Revenue	3.82%	-5.02%	-9.86%	-9.54%	-5.86%	-0.21%	-6.75%	-3.32%	-2.44%	-3.50%
Debt-free Net Working Capital to Revenue	48.57%	34.12%	87.85%	126.45%	102.61%	29.79%	17.13%	20.08%	24.35%	31.24%
Net Working Capital to Revenue	45.57%	34.12%	77.33%	114.03%	91.48%	18.63%	11.58%	11.75%	17.72%	24.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$12.37	$10.08	$3.54	$4.20	$4.24	$0.10	$4.96	$3.66	$4.54	$0.38
Adjusted Weighted Average Basic Shares Outstanding	1.46B	1.34B	1.31B	1.30B	1.27B	1.26B	1.26B	1.26B	1.25B	1.25B
Adjusted Diluted Earnings per Share	$11.91	$9.94	$3.51	$4.17	$4.22	$0.10	$4.93	$3.64	$4.50	$0.38
Adjusted Weighted Average Diluted Shares Outstanding	1.52B	1.36B	1.32B	1.31B	1.28B	1.26B	1.26B	1.26B	1.26B	1.26B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.37B	1.31B	1.31B	1.28B	1.26B	1.26B	1.25B	1.25B	1.25B	1.25B
Normalized Net Operating Profit after Tax (NOPAT)	18,552	13,911	9,887	5,741	3,001	2,850	7,430	7,877	6,263	4,056
Normalized NOPAT Margin	56.84%	45.77%	37.87%	25.94%	13.37%	11.54%	27.21%	28.87%	23.10%	14.10%
Pre Tax Income Margin	66.36%	56.26%	51.82%	35.25%	22.99%	6.76%	30.32%	21.31%	25.30%	2.40%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	32.48	18.74	13.10	8.24	6.19	2.70	9.27	7.22	8.27	1.71
NOPAT to Interest Expense	26.97	14.43	4.34	5.33	4.48	0.22	7.42	6.16	6.59	1.18
EBIT Less CapEx to Interest Expense	31.40	17.96	12.57	7.38	5.36	2.04	8.69	6.44	7.65	1.17
NOPAT Less CapEx to Interest Expense	25.88	13.65	3.81	4.47	3.65	-0.44	6.84	5.38	5.97	0.65
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	10.35%	18.20%	58.81%	54.41%	60.07%	3,875.28%	58.14%	81.23%	67.86%	816.25%
Augmented Payout Ratio	65.59%	99.76%	79.35%	107.53%	92.67%	5,653.93%	66.94%	111.80%	85.68%	1,055.83%

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-5.11%	2.00%	-3.61%	5.42%	0.13%	-3.72%	5.26%	5.38%	7.01%	6.40%
EBITDA Growth	-24.34%	81.79%	255.32%	10.04%	1.54%	-6.93%	-263.10%	19.42%	-41.76%	19.95%
EBIT Growth	-27.85%	126.38%	1,680.23%	4.13%	-4.13%	-15.64%	-376.36%	25.98%	-53.19%	26.89%
NOPAT Growth	-27.91%	291.43%	835.86%	-28.90%	17.97%	-24.19%	-334.43%	90.93%	-52.65%	45.92%
Net Income Growth	-30.94%	334.31%	8,108.33%	-8.46%	21.61%	-13.23%	-523.35%	55.34%	-42.31%	25.83%
EPS Growth	-30.73%	330.00%	3,900.00%	-8.79%	21.83%	-11.63%	-517.50%	55.42%	-42.20%	25.44%
Operating Cash Flow Growth	-11.99%	-19.91%	-5.22%	29.74%	-38.70%	-15.50%	27.24%	-43.33%	145.53%	37.16%
Free Cash Flow Firm Growth	127.06%	30.91%	-53.95%	-52.86%	-48.85%	-70.04%	-217.42%	-24.51%	45.32%	507.74%
Invested Capital Growth	-7.05%	-2.81%	-0.99%	-2.77%	-0.34%	1.29%	-2.70%	1.13%	-6.63%	-8.50%
Revenue Q/Q Growth	12.49%	4.93%	-14.03%	3.89%	6.85%	0.89%	-6.02%	4.01%	8.50%	0.32%
EBITDA Q/Q Growth	40.35%	-12.59%	-22.05%	15.06%	29.50%	-19.88%	-236.61%	184.24%	-36.84%	65.02%
EBIT Q/Q Growth	52.49%	-15.18%	-32.17%	18.68%	40.40%	-25.36%	-322.22%	154.10%	-47.84%	102.35%
NOPAT Q/Q Growth	35.97%	-12.51%	-29.20%	-15.59%	125.61%	-43.78%	-318.94%	168.75%	-44.04%	73.25%
Net Income Q/Q Growth	57.36%	-8.57%	-39.68%	5.48%	109.05%	-34.76%	-394.28%	138.71%	-22.37%	42.30%
EPS Q/Q Growth	56.04%	-9.15%	-37.98%	3.75%	108.43%	-34.10%	-392.98%	138.62%	-22.48%	43.00%
Operating Cash Flow Q/Q Growth	58.88%	-10.34%	-32.06%	34.06%	-24.94%	23.59%	2.31%	-40.29%	225.21%	-30.96%
Free Cash Flow Firm Q/Q Growth	9.52%	-41.89%	-42.88%	29.66%	18.82%	-65.96%	-323.89%	183.36%	128.74%	42.35%
Invested Capital Q/Q Growth	-0.24%	-1.34%	0.44%	-1.64%	2.26%	0.27%	-3.51%	2.23%	-5.60%	-1.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.19%	81.11%	77.94%	78.15%	77.80%	70.62%	76.79%	77.80%	79.14%	79.11%
EBITDA Margin	45.24%	37.69%	34.18%	37.85%	45.88%	36.44%	-52.96%	42.90%	24.97%	41.08%
Operating Margin	40.29%	30.68%	26.84%	25.23%	37.20%	22.66%	-64.64%	38.02%	11.77%	32.40%
EBIT Margin	37.79%	30.55%	24.10%	27.53%	36.18%	26.76%	-63.28%	32.92%	15.83%	31.92%
Profit (Net Income) Margin	25.36%	22.10%	15.51%	15.74%	30.80%	19.92%	-62.37%	23.21%	16.61%	23.56%
Tax Burden Percent	73.44%	80.40%	75.77%	65.43%	93.70%	85.72%	92.96%	78.62%	131.07%	82.28%
Interest Burden Percent	91.39%	89.99%	84.91%	87.40%	90.87%	86.82%	106.03%	89.69%	80.07%	89.69%
Effective Tax Rate	26.56%	19.60%	24.31%	34.57%	6.30%	14.28%	0.00%	21.33%	-31.07%	17.77%
Return on Invested Capital (ROIC)	19.66%	17.09%	14.03%	11.62%	24.31%	13.49%	-32.30%	21.57%	11.52%	20.35%
ROIC Less NNEP Spread (ROIC-NNEP)	18.14%	16.05%	12.40%	11.35%	22.69%	13.69%	-38.24%	19.11%	12.02%	18.95%
Return on Net Nonoperating Assets (RNNOA)	16.69%	13.85%	11.38%	10.02%	18.47%	10.64%	-38.36%	18.39%	10.41%	15.02%
Return on Equity (ROE)	36.36%	30.94%	25.40%	21.64%	42.78%	24.12%	-70.67%	39.96%	21.93%	35.37%
Cash Return on Invested Capital (CROIC)	18.02%	17.47%	18.19%	18.94%	17.28%	14.65%	4.48%	3.33%	8.27%	11.95%
Operating Return on Assets (OROA)	15.82%	12.71%	10.43%	12.04%	15.86%	11.58%	-29.40%	15.79%	7.66%	15.16%
Return on Assets (ROA)	10.62%	9.20%	6.71%	6.89%	13.51%	8.62%	-28.98%	11.13%	8.04%	11.18%
Return on Common Equity (ROCE)	36.38%	30.97%	25.45%	21.69%	42.88%	24.19%	-70.93%	40.11%	22.01%	35.51%
Return on Equity Simple (ROE_SIMPLE)	15.70%	0.00%	26.38%	25.73%	26.12%	0.00%	2.61%	5.65%	0.62%	0.00%
Net Operating Profit after Tax (NOPAT)	2,083	1,823	1,291	1,089	2,458	1,382	-3,025	2,080	1,164	2,016
NOPAT Margin	29.59%	24.67%	20.32%	16.51%	34.86%	19.42%	-45.25%	29.91%	15.43%	26.64%
Net Nonoperating Expense Percent (NNEP)	1.52%	1.04%	1.63%	0.28%	1.62%	-0.21%	5.94%	2.46%	-0.51%	1.40%
Return On Investment Capital (ROIC_SIMPLE)	-	3.93%	-	-	-	2.89%	-	-	-	4.39%
Cost of Revenue to Revenue	19.81%	18.89%	22.06%	21.85%	22.20%	29.38%	23.21%	22.20%	20.86%	20.89%
SG&A Expenses to Revenue	17.23%	27.34%	20.77%	28.02%	18.65%	22.59%	20.57%	19.80%	18.99%	25.18%
R&D to Revenue	22.68%	23.09%	30.35%	24.90%	21.95%	24.66%	84.52%	19.97%	25.18%	21.54%
Operating Expenses to Revenue	39.90%	50.43%	51.12%	52.92%	40.60%	47.95%	141.43%	39.78%	67.37%	46.72%
Earnings before Interest and Taxes (EBIT)	2,661	2,257	1,531	1,817	2,551	1,904	-4,231	2,289	1,194	2,416
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,186	2,785	2,171	2,498	3,235	2,592	-3,541	2,983	1,884	3,109
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.42	4.69	4.68	4.36	4.02	4.25	5.14	4.68	5.65	5.96
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.66	3.65	3.64	3.37	3.27	3.58	3.28	3.07	3.69	4.00
Price to Earnings (P/E)	21.66	21.69	17.62	16.82	15.26	17.12	185.91	81.10	821.89	239.83
Dividend Yield	5.03%	3.68%	3.73%	4.00%	4.14%	3.85%	4.17%	4.43%	3.65%	3.33%
Earnings Yield	4.62%	4.61%	5.68%	5.94%	6.55%	5.84%	0.54%	1.23%	0.12%	0.42%
Enterprise Value to Invested Capital (EV/IC)	2.30	3.02	2.98	2.85	2.72	2.89	2.91	2.73	3.35	3.66
Enterprise Value to Revenue (EV/Rev)	3.33	4.30	4.30	4.00	3.89	4.18	4.03	3.81	4.33	4.58
Enterprise Value to EBITDA (EV/EBITDA)	11.90	13.24	11.17	10.29	9.97	10.81	23.11	20.11	31.27	29.71
Enterprise Value to EBIT (EV/EBIT)	16.48	17.36	14.20	13.24	13.06	14.54	54.17	42.17	105.98	78.99
Enterprise Value to NOPAT (EV/NOPAT)	20.68	20.35	17.27	17.44	16.02	18.23	164.50	61.70	230.09	114.19
Enterprise Value to Operating Cash Flow (EV/OCF)	9.32	12.92	12.96	11.50	12.68	14.17	13.04	14.19	12.22	12.17
Enterprise Value to Free Cash Flow (EV/FCFF)	12.30	17.04	16.32	14.86	15.70	19.83	64.16	82.57	39.10	29.30
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.20	1.19	1.21	1.20	1.12	1.10	1.44	1.28	1.26	1.39
Long-Term Debt to Equity	1.09	1.08	1.10	1.01	1.04	1.02	1.23	1.18	1.17	1.29
Financial Leverage	0.92	0.86	0.92	0.88	0.81	0.78	1.00	0.96	0.87	0.79
Leverage Ratio	3.05	3.10	3.06	3.03	2.89	2.85	3.08	2.95	2.88	2.88
Compound Leverage Factor	2.79	2.79	2.60	2.65	2.62	2.47	3.26	2.65	2.30	2.59
Debt to Total Capital	54.50%	54.33%	54.66%	54.48%	52.90%	52.34%	59.07%	56.20%	55.83%	58.12%
Short-Term Debt to Total Capital	4.90%	4.89%	4.94%	8.71%	3.80%	3.77%	8.60%	4.36%	4.35%	3.95%
Long-Term Debt to Total Capital	49.60%	49.43%	49.71%	45.77%	49.10%	48.58%	50.47%	51.84%	51.48%	54.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.05%	-0.07%	-0.13%	-0.14%	-0.15%	-0.18%	-0.20%	-0.20%	-0.20%	-0.18%
Common Equity to Total Capital	45.55%	45.74%	45.47%	45.66%	47.25%	47.83%	41.12%	44.00%	44.37%	42.06%
Debt to EBITDA	3.32	2.85	2.42	2.37	2.34	2.38	5.27	4.43	5.93	6.02
Net Debt to EBITDA	2.41	1.99	1.73	1.62	1.59	1.58	4.28	3.91	4.65	3.77
Long-Term Debt to EBITDA	3.02	2.59	2.20	1.99	2.17	2.21	4.50	4.09	5.47	5.61
Debt to NOPAT	5.77	4.38	3.75	4.02	3.76	4.02	37.49	13.60	43.67	23.15
Net Debt to NOPAT	4.18	3.06	2.68	2.75	2.55	2.66	30.47	11.98	34.21	14.49
Long-Term Debt to NOPAT	5.25	3.99	3.41	3.38	3.49	3.73	32.03	12.54	40.26	21.58
Altman Z-Score	2.03	2.38	2.36	2.22	2.35	2.48	1.92	2.44	2.68	2.78
Noncontrolling Interest Sharing Ratio	-0.05%	-0.09%	-0.17%	-0.20%	-0.22%	-0.26%	-0.37%	-0.37%	-0.38%	-0.40%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.30	1.29	1.28	1.02	1.34	1.43	1.08	1.14	1.26	1.60
Quick Ratio	0.96	0.99	0.95	0.78	0.98	1.06	0.72	0.69	0.82	1.20
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5,065	2,944	1,682	2,180	2,591	882	-1,974	1,646	3,765	5,359
Operating Cash Flow to CapEx	1,823.57%	1,418.23%	1,600.00%	1,682.01%	1,438.52%	1,008.84%	2,113.33%	1,019.23%	3,056.03%	2,023.81%
Free Cash Flow to Firm to Interest Expense	22.12	13.03	7.31	9.48	11.17	3.50	-7.77	6.94	15.82	21.61
Operating Cash Flow to Interest Expense	12.50	11.36	7.58	10.17	7.56	8.61	8.74	5.59	18.11	12.00
Operating Cash Flow Less CapEx to Interest Expense	11.82	10.56	7.11	9.56	7.04	7.75	8.32	5.04	17.51	11.40
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.42	0.42	0.43	0.44	0.44	0.43	0.46	0.48	0.48	0.47
Accounts Receivable Turnover	6.08	5.89	6.80	6.56	5.99	5.75	6.22	6.25	6.04	6.33
Inventory Turnover	4.39	3.62	3.68	3.60	3.71	3.95	3.88	3.69	3.83	3.58
Fixed Asset Turnover	5.23	5.15	5.04	5.05	5.02	5.03	5.08	5.11	5.16	5.36
Accounts Payable Turnover	11.49	7.03	9.31	9.49	9.67	8.93	10.65	11.65	9.08	9.04
Days Sales Outstanding (DSO)	59.99	62.01	53.64	55.63	60.92	63.51	58.71	58.36	60.47	57.63
Days Inventory Outstanding (DIO)	83.17	100.82	99.06	101.29	98.29	92.51	94.12	98.91	95.35	102.10
Days Payable Outstanding (DPO)	31.77	51.94	39.20	38.45	37.73	40.86	34.28	31.33	40.20	40.38
Cash Conversion Cycle (CCC)	111.39	110.89	113.51	118.47	121.49	115.16	118.55	125.95	115.63	119.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	39,338	38,809	38,980	38,340	39,205	39,309	37,929	38,774	36,604	35,966
Invested Capital Turnover	0.66	0.69	0.69	0.70	0.70	0.69	0.71	0.72	0.75	0.76
Increase / (Decrease) in Invested Capital	-2,982	-1,121	-391	-1,091	-133	500	-1,051	434	-2,601	-3,343
Enterprise Value (EV)	90,455	117,171	116,329	109,435	106,538	113,455	110,559	105,972	122,508	131,754
Market Capitalization	72,198	99,602	98,347	92,254	89,648	96,979	90,167	85,478	104,380	115,118
Book Value per Share	$16.82	$16.93	$16.84	$16.96	$17.91	$18.32	$14.07	$14.67	$14.84	$15.51
Tangible Book Value per Share	($13.30)	($12.73)	($12.56)	($11.95)	($10.56)	($9.58)	($11.39)	($10.33)	($8.34)	($7.17)
Total Capital	46,280	46,439	46,178	46,340	47,224	47,736	42,649	41,547	41,639	45,957
Total Debt	25,223	25,230	25,239	25,246	24,982	24,987	25,194	23,350	23,249	26,711
Total Long-Term Debt	22,953	22,957	22,956	21,209	23,189	23,189	21,527	21,540	21,437	24,896
Net Debt	18,281	17,600	18,040	17,245	16,962	16,560	20,476	20,578	18,212	16,720
Capital Expenditures (CapEx)	157	181	109	139	122	215	105	130	141	147
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-259	-906	-661	-2,307	-1,036	-661	-25	574	-171	-1,007
Debt-free Net Working Capital (DFNWC)	5,401	5,479	5,211	4,360	5,828	6,603	4,693	3,346	4,866	8,984
Net Working Capital (NWC)	3,131	3,206	2,928	323	4,035	4,805	1,026	1,536	3,054	7,169
Net Nonoperating Expense (NNE)	297	190	306	50	286	-35	1,145	466	-89	233
Net Nonoperating Obligations (NNO)	18,281	17,600	18,041	17,246	16,963	16,560	20,474	20,577	18,214	16,720
Total Depreciation and Amortization (D&A)	525	528	640	681	684	688	690	694	690	693
Debt-free, Cash-free Net Working Capital to Revenue	-0.95%	-3.32%	-2.44%	-8.43%	-3.78%	-2.44%	-0.09%	2.06%	-0.60%	-3.50%
Debt-free Net Working Capital to Revenue	19.90%	20.08%	19.27%	15.92%	21.28%	24.35%	17.10%	12.03%	17.20%	31.24%
Net Working Capital to Revenue	11.54%	11.75%	10.83%	1.18%	14.73%	17.72%	3.74%	5.52%	10.79%	24.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.43	$1.30	$0.81	$0.84	$1.75	$1.14	($3.34)	$1.29	$1.00	$1.43
Adjusted Weighted Average Basic Shares Outstanding	1.26B	1.26B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B
Adjusted Diluted Earnings per Share	$1.42	$1.29	$0.80	$0.83	$1.73	$1.14	($3.34)	$1.29	$1.00	$1.43
Adjusted Weighted Average Diluted Shares Outstanding	1.26B	1.26B	1.26B	1.26B	1.26B	1.26B	1.25B	1.25B	1.25B	1.26B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.24B	1.25B	1.25B
Normalized Net Operating Profit after Tax (NOPAT)	2,083	1,823	1,291	1,089	2,458	1,425	-1,324	2,080	1,847	2,016
Normalized NOPAT Margin	29.59%	24.67%	20.32%	16.51%	34.86%	20.03%	-19.81%	29.91%	24.47%	26.64%
Pre Tax Income Margin	34.54%	27.49%	20.47%	24.06%	32.87%	23.24%	-67.10%	29.52%	12.67%	28.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	11.62	9.99	6.66	7.90	11.00	7.56	-16.66	9.66	5.02	9.74
NOPAT to Interest Expense	9.10	8.07	5.61	4.74	10.59	5.48	-11.91	8.78	4.89	8.13
EBIT Less CapEx to Interest Expense	10.93	9.19	6.18	7.30	10.47	6.70	-17.07	9.11	4.42	9.15
NOPAT Less CapEx to Interest Expense	8.41	7.26	5.14	4.13	10.07	4.63	-12.32	8.23	4.30	7.54
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	111.45%	81.23%	67.39%	69.02%	64.87%	67.86%	836.24%	373.48%	3,410.53%	816.25%
Augmented Payout Ratio	131.19%	111.80%	93.46%	96.99%	93.03%	85.68%	1,054.59%	465.44%	4,243.86%	1,055.83%

Frequently Asked Questions About Gilead Sciences' Financials

When does Gilead Sciences's fiscal year end?

According to the most recent income statement we have on file, Gilead Sciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Gilead Sciences' net income changed over the last 9 years?

Gilead Sciences' net income appears to be on a downward trend, with a most recent value of $480 million in 2024, falling from $18.11 billion in 2015. The previous period was $5.61 billion in 2023.

What is Gilead Sciences's operating income?

Gilead Sciences's total operating income in 2024 was $1.66 billion, based on the following breakdown:

Total Gross Profit: $22.50 billion
Total Operating Expenses: $20.84 billion

How has Gilead Sciences revenue changed over the last 9 years?

Over the last 9 years, Gilead Sciences' total revenue changed from $32.64 billion in 2015 to $28.75 billion in 2024, a change of -11.9%.

How much debt does Gilead Sciences have?

Gilead Sciences' total liabilities were at $39.75 billion at the end of 2024, a 0.9% increase from 2023, and a 21.9% increase since 2015.

How much cash does Gilead Sciences have?

In the past 9 years, Gilead Sciences' cash and equivalents has ranged from $5.34 billion in 2021 to $17.94 billion in 2018, and is currently $9.99 billion as of their latest financial filing in 2024.

How has Gilead Sciences' book value per share changed over the last 9 years?

Over the last 9 years, Gilead Sciences' book value per share changed from 12.86 in 2015 to 15.51 in 2024, a change of 20.6%.

Remove Ads

Related Companies

This page (NASDAQ:GILD) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Financials

Frequently Asked Questions About Gilead Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Financials

Annual Income Statements for Gilead Sciences

Quarterly Income Statements for Gilead Sciences

Annual Cash Flow Statements for Gilead Sciences

Quarterly Cash Flow Statements for Gilead Sciences

Annual Balance Sheets for Gilead Sciences

Quarterly Balance Sheets for Gilead Sciences

Annual Metrics and Ratios for Gilead Sciences

Quarterly Metrics and Ratios for Gilead Sciences

Frequently Asked Questions About Gilead Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools